

Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 December 2023
for
THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER
(A COMPANY LIMITED BY GUARANTEE)

Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Contents of the Financial Statements
for the year ended 31 DECEMBER 2023

	Page
Report of the Trustees	1 to 5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance Sheet	8 to 9
Cash Flow Statement	10
Notes to the Cash Flow Statement	11
Notes to the Financial Statements	12 to 18
Detailed Statement of Financial Activities	19

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2023

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014 (as amended by Update Bulletin 1 published on 2 February 2016).

OBJECTIVES AND ACTIVITIES

Objectives and aims

The objectives of the company, as set out in the Memorandum of Association as amended by Special Resolution, are to advance education and awareness in liver disease and disorder, by the provision or the facilitation of research directed towards the development and evaluation of treatment of such disease and disorders. The trustees confirm that they have referred to the guidance contained in the Charity Commission's guidance on public benefit when reviewing the association's aims and objectives and in planning future activities.

The Trustees carry out these objects by:

- Having educational meetings for medical professionals to attend to further their knowledge and advance education, awareness and research into liver disease.
- Supporting special interest groups to further education of specific areas of liver disease.

To assess success in the reporting period, BASL aim to maintain and increase membership, provide educational events; predominantly the Annual Scientific Meeting. To maintain sufficient funds to allow these activities to take place.

Contribution

The contribution of each member is limited to £1 in the event of a dissolution of the Company.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2023

STRATEGIC REPORT

Achievement and performance

Charitable activities

BASL Annual Meeting (incorporating the annual BTLG and BLNA meeting)

The 2023 BASL Annual meeting was held at the DoubleTree Metropole in Brighton and proved to be a great success providing interaction and learning opportunities. There were 639 delegates across all three meetings which made an excellent surplus. The Sheila Sherlock prize went to Dr Kushala Abeysekera and Dr Oliver Tavabie received the Andrew Burroughs Young Investigator award.

BASL Schools

BASL Schools are small group meetings provided free of charge to trainee members in Gastroenterology and Hepatology that deliver structured education and interaction with experts in the field. These help the charity to meet its objectives by committing to improving clinical education and training for tomorrow's Hepatology Consultants, Trainees interested in transplantation and anaesthesia.

These were held as 6 interactive Webinars. These proved to be a great success and feedback was excellent.

BASL Xtra

This is an online educational conference and was the second one to be held. This a multi-professional, topic focused educational online event. Attendance and surplus were excellent and the decision was made to continue to hold this event annually.

BASL Introduction to Hepatology Day

The meeting was held in Birmingham. This was deemed to be a great success and provided a small surplus.

BVHG Meetings

Two meetings were held in 2023 due to the 2022 meeting being delayed until January 2023. These meetings were very popular and provided an excellent surplus.

BASL Basic Science Retreat

This was held in London and any shortfall was covered by the Institute of Hepatology, who organised the event on behalf of BASL. This was very popular and well attended.

Special Interest Groups

BASL provides ongoing administrative support to a number of established Special Interest Groups (SIGs) whose remit is to promote and encourage collaborative research and clinical trials in liver disease.

HCC-UK Annual Meeting

This was held at the Royal College of Physicians in Edinburgh. This was very well attended and made an excellent surplus.

CCA-UK Annual Meeting

This was held in Nottingham and made a significant deficit. Changes were made to future format for this meeting to prevent more deficit.

BAAL

This was the first meeting for this newly formed group, held in Birmingham. Costs were covered and a small surplus was made.

BHPG Educational Meeting

Meetings were held in February and November in 2023 and a good surplus was made due to good sponsorship being achieved.

Secretariat

Secretariat services were provided by Executive Business Support Ltd.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2023

To ensure a balanced picture of the charity's progress against its objectives, sufficient funds are maintained to allow the Desired educational events held to continue to take place.

The key performance indicators to explain outputs achieved by activities are the level and numbers of members increasing, as well as maintaining delegate members at educational events.

Financial review

Financial position

Detailed finance reports are produced for the Trustees for every governing board meeting. The Trustees aim to achieve a Surplus or Breakeven for every educational meeting. The results for the year are shown on page 16. The trustees aim to hold sufficient reserves to support key meetings in the event of potential shortfalls in income. The membership and subscriptions database has been updated and clarified and the charity currently has 1,624 (2022: 1,423) active members. The BASL website continued to provide a good platform for providing news and information as well as serving as an interactive communications and education hub for members.

The charity managed to achieve income of £533,539 (2022: £397,892) during the year.

Cash reserves have been stable at £261,210 (2022: £206,737) due to the charity continuing to hold events on a virtual basis, as well as face to face, resulting in lower costs as a result and in addition, increasing membership fees.

The trustees believe that the charity has sufficient reserves to continue and hopes to achieve a greater surplus in 2024 with the aim of holding events on a face to face basis, as well as some on a virtual basis. The charity always hopes to retain reserves in unrestricted funds to cover 24 months operational costs and at the end of the accounting period, these had decreased to £173,615 (2022: £125,001). It is hoped that reserves will return to former levels over the next two years and be able to cover 24 months of operational costs during the 2024 and 2025 accounting periods.

Significant events that have affected financial performance and financial position during the period, include an increase in face to face meetings held, following more virtual events during 2020 - 2022 due to Covid. This resulted in an increase in costs to hold meetings as well as increased sponsorship and delegate income. Close attention is made to ensure all events held make a surplus or at the very least cost neutral. Factors likely to affect future financial performance or position are the advancement in medical science resulting in an increase in education of the members and potential increase in sponsorship from Pharmaceutical companies to promote new treatments. Principal funding sources are the membership income as well as sponsorship from Pharmaceutical companies and delegate income from events.

Reserves policy

Reserves are needed as sponsorship by Pharmaceutical companies of educational events, which are one of the key objectives of BASL, can drop suddenly depending on the current focus of the Pharmaceutical Companies. As stated in the Articles of Association: The Association will aim to retain sufficient capital funds in reserve to permit it to conduct its activities as defined by the Governing Board for a period of two years in the absence of any income over this period.

Future Developments

The Trustees aim to continue to provide educational meetings and other member benefits in accordance with the objectives of the Charity. The experience of the pandemic has resulted in the ability to run meetings on a virtual basis to ensure events still take place, making meetings accessible to members and meaning external risk factors are more manageable.

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Report of the Trustees
for the year ended 31 DECEMBER 2023

STRUCTURE, GOVERNANCE AND MANAGEMENT

Induction and training of new trustees

Newly elected trustees attend quarterly meetings with the Chairperson and the governing board to observe the provision of services to members. They are also given guidance which include an outline of their role and a handover from the outgoing Trustee.

The charity makes decisions through its governing board. Policies and procedures for induction and training of trustees is supported by the current and outgoing Trustees.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Company number

05017662 (England and Wales)

Registered Charity number

1106320

Registered office

Executive Business Support
Davidson Road
Lichfield
Staffordshire
WS14 9DZ

Trustees

Dr T J S Cross Consultant Hepatologist (appointed 22.9.23)
Professor B R Davidson Hepatobiliary and Transplant Consultant (resigned 22.9.23)
Dr T J Kendall Senior Clinical Fellow In Pathology
Dr I A C Rowe University Clinical Academic Fellow
Dr V Snowdon Consultant Hepatologist
Ms M B Clayton Lecturer In Liver Care
Dr M A Aldersley Consultant Hepatologist (resigned 1.2.23)
Dr K J Simpson Consultant Physician and Senior Lecturer (resigned 1.10.23)
Professor M E Cramp Consultant Hepatologist
Dr A M Elsharkawy Consultant Hepatologist
Dr R Jones Consultant Hepatologist (resigned 22.9.23)
Dr K Drysale Hepatology Registrar Clinical Research (resigned 31.1.23)
Professor R Mookerjee Professor of Translational Hepatology
Dr M Allison Consultant Hepatologist
Dr S Chokshi Acting Director & Chief Scientific Officer
Dr O A A Elshaarawy (appointed 18.5.23)
Professor P Kennedy Consultant Hepatologist and Gastroentero (appointed 30.1.23)
Mr J A Richard Doctor (appointed 31.10.23)


Independent Examiner

Carl Elsby ACA
Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Report of the Trustees
for the year ended 31 DECEMBER 2023**

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 19-JAN-2024..... and signed on the board's behalf by:


.....
Dr A M Elsharkawy - Trustee

Independent Examiner's Report to the Trustees of
The British Association for the Study of
the Liver

Independent examiner's report to the trustees of The British Association for the Study of the Liver ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2023.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Carl Elsby ACA

Elsby & Co (Sywell) Ltd
Chartered Accountants
155 Wellingborough Road
Rushden
Northamptonshire
NN10 9TB

Date: 1st October 2024

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Statement of Financial Activities
for the year ended 31 DECEMBER 2023**

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
INCOME AND ENDOWMENTS FROM					
Membership subscriptions	3	116,383	-	116,383	99,160
Conference fees & sponsorship income	4	413,049	-	413,049	297,904
Interest receivable	5	4,107	-	4,107	828
Total		<u>533,539</u>	<u>-</u>	<u>533,539</u>	<u>397,892</u>
 EXPENDITURE ON					
Conference costs					
Direct conference costs	6	287,534	-	287,534	206,048
Other associated conference costs	7	189,113	-	189,113	197,398
		<u>476,647</u>	<u>-</u>	<u>476,647</u>	<u>403,446</u>
Other		<u>9,014</u>	<u>-</u>	<u>9,014</u>	<u>13,476</u>
Total		<u>485,661</u>	<u>-</u>	<u>485,661</u>	<u>416,922</u>
 NET INCOME/(EXPENDITURE)		<u>47,878</u>	<u>-</u>	<u>47,878</u>	<u>(19,030)</u>
 RECONCILIATION OF FUNDS					
Total funds brought forward		<u>125,001</u>	<u>22,377</u>	<u>147,378</u>	<u>166,408</u>
 TOTAL FUNDS CARRIED FORWARD		<u><u>172,879</u></u>	<u><u>22,377</u></u>	<u><u>195,256</u></u>	<u><u>147,378</u></u>

CONTINUING OPERATIONS

All income and expenditure has arisen from continuing activities.

The notes form part of these financial statements

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Balance Sheet
31 DECEMBER 2023**

	Notes	Unrestricted funds £	Restricted funds £	2023 Total funds £	2022 Total funds £
FIXED ASSETS					
Investments	12	1	-	1	1
CURRENT ASSETS					
Debtors: amounts falling due within one year	13	40,753	-	40,753	17,893
Cash at bank		238,833	22,377	261,210	206,737
		<u>279,586</u>	<u>22,377</u>	<u>301,963</u>	<u>224,630</u>
CREDITORS					
Amounts falling due within one year	14	(69,926)	-	(69,926)	(45,129)
		<u>209,660</u>	<u>22,377</u>	<u>232,037</u>	<u>179,501</u>
NET CURRENT ASSETS					
		<u>209,661</u>	<u>22,377</u>	<u>232,038</u>	<u>179,502</u>
TOTAL ASSETS LESS CURRENT LIABILITIES					
		<u>209,661</u>	<u>22,377</u>	<u>232,038</u>	<u>179,502</u>
CREDITORS					
Amounts falling due after more than one year	15	(36,782)	-	(36,782)	(32,124)
		<u>172,879</u>	<u>22,377</u>	<u>195,256</u>	<u>147,378</u>
NET ASSETS					
		<u>172,879</u>	<u>22,377</u>	<u>195,256</u>	<u>147,378</u>
FUNDS	16				
Unrestricted funds:					
General fund				172,879	125,001
Restricted funds:					
BASL nurses fund				6,627	6,627
CCA UK Neil Blenkinsop donation for research only				15,750	15,750
				<u>22,377</u>	<u>22,377</u>
TOTAL FUNDS				<u>195,256</u>	<u>147,378</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The notes form part of these financial statements


THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Balance Sheet - continued
31 DECEMBER 2023

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees and authorised for issue on 19 SEP 2024 and were signed on its behalf by:


Dr A M Elsharkawy - Trustee

The notes form part of these financial statements

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Cash Flow Statement
for the year ended 31 DECEMBER 2023**

	Notes	2023 £	2022 £
Cash flows from operating activities			
Cash generated from operations	1	50,366	(5,449)
Net cash provided by/(used in) operating activities		50,366	(5,449)
Cash flows from investing activities			
Interest received		4,107	828
Net cash provided by investing activities		4,107	828
Change in cash and cash equivalents in the reporting period		54,473	(4,621)
Cash and cash equivalents at the beginning of the reporting period		206,737	211,358
Cash and cash equivalents at the end of the reporting period		261,210	206,737

The notes form part of these financial statements

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Cash Flow Statement
for the year ended 31 DECEMBER 2023**

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2023 £	2022 £
Net income/(expenditure) for the reporting period (as per the Statement of Financial Activities)	47,878	(19,030)
Adjustments for:		
Interest received	(4,107)	(828)
Increase in debtors	(22,860)	(3,429)
Increase in creditors	29,455	17,838
	<u>50,366</u>	<u>(5,449)</u>
Net cash provided by/(used in) operations	<u><u>50,366</u></u>	<u><u>(5,449)</u></u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.1.23 £	Cash flow £	At 31.12.23 £
Net cash			
Cash at bank	206,737	54,473	261,210
	<u>206,737</u>	<u>54,473</u>	<u>261,210</u>
Total	<u><u>206,737</u></u>	<u><u>54,473</u></u>	<u><u>261,210</u></u>

The notes form part of these financial statements

THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER

Notes to the Financial Statements
for the year ended 31 DECEMBER 2023

1. ACCOUNTING POLICIES

General information

The charity is a private company limited by guarantee, registered in England and Wales and a registered charity in England and Wales. The address of the registered office is Executive Business Support, Davidson Road, Lichfield, Staffordshire, England, WS14 9DZ.

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

The presentational currency of BASL is considered to be pounds sterling and the financial statements are rounded to the nearest pound.

Incoming resources

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Income received for a specific restricted purpose is credited to a separate restricted fund which is shown in a note to the financial statements. Total incoming resources credited to restricted funds are disclosed on the statement of financial activities which also shows incoming resources in respect of unrestricted funds.

Conference income represents fees and sponsorship received in respect of conference's organised in pursuit of the company's charitable objectives.

Income associated with conferences of future accounting periods is treated as deferred income.

Resources expended

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Resources expended are included in the statement of financial activities on an accrual basis exclusive of VAT. All irrecoverable VAT is charged against the category of resources expended for which it was incurred.

Taxation

The activities of the charity are exempt from Corporation Tax under Section 505 of the Income and Corporation Taxes Act 1988 to the extent that they are applied to the organisation's charitable objects.

Fund accounting

Unrestricted funds are donations and other incoming resources received or generated for the general charitable purposes of the charity.

Within unrestricted funds are designated funds. The nature of each of the designated funds is referred to within the report of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

1. ACCOUNTING POLICIES - continued

Debtors and creditors

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

Cash and cash equivalents

Cash and cash equivalents include cash in hand and deposits held at call with banks.

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In preparing the financial statements it is necessary to make certain judgements, estimates and assumptions that affect the amounts recognised in the financial statements.

In the view of the trustees in applying the accounting policies adopted, no judgements were required that have a significant effect on the amounts recognised in the financial statements nor do any estimates or assumptions made carry a significant risk of material adjustment in the next financial year.

3. MEMBERSHIP SUBSCRIPTIONS

	2023	2022
	£	£
Grants	12,729	-
Subscriptions	103,654	99,160
	<u>116,383</u>	<u>99,160</u>

Grants receivable are credited to the Statement of Financial Activities (SOFA) in the year for the year for which they are received. Deferred income represents amounts received for future periods and is released to incoming resources in the period for which it has been received.

4. CONFERENCE FEES & SPONSORSHIP INCOME

	2023	2022
	£	£
Conference income	<u>413,049</u>	<u>297,904</u>

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

5. INTEREST RECEIVABLE	2023	2022
	£	£
Interest receivable	<u>4,107</u>	<u>828</u>
6. DIRECT CONFERENCE COSTS	2023	2022
	£	£
Annual conference costs	274,284	194,548
Annual support to UKLA	<u>13,250</u>	<u>11,500</u>
	<u>287,534</u>	<u>206,048</u>
7. OTHER ASSOCIATED CONFERENCE COSTS	2023	2022
	£	£
Travel & hotels	12,511	2,242
Artwork/design & print	4,216	3,536
CPD application	956	284
Bank charges	5,282	4,196
Website	4,408	6,185
Secretarial support costs	8,044	5,751
EBS Costs	170,635	175,204
Partial exemption input VAT	<u>(16,939)</u>	<u>-</u>
	<u>189,113</u>	<u>197,398</u>
8. SUPPORT COSTS		Governance costs
		£
Other resources expended		<u>9,014</u>
9. NET INCOME/(EXPENDITURE)		
Net income/(expenditure) is stated after charging/(crediting):		
	2023	2022
	£	£
Accountancy fees	<u>5,012</u>	<u>5,047</u>

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

10. TRUSTEES' REMUNERATION AND BENEFITS

No trustees received any remuneration during the current or prior year.

Trustees' expenses

Travel and speaker expenses totalling £525.36 (2022; £728.30) were reimbursed to 4 (2022; 4) trustees during the year.

11. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Membership subscriptions	99,160	-	99,160
Conference fees & sponsorship income	297,904	-	297,904
Interest receivable	828	-	828
Total	397,892	-	397,892
EXPENDITURE ON			
Conference costs			
Direct conference costs	206,048	-	206,048
Other associated conference costs	197,398	-	197,398
	403,446	-	403,446
Other	13,476	-	13,476
Total	416,922	-	416,922
NET INCOME/(EXPENDITURE)	(19,030)	-	(19,030)
RECONCILIATION OF FUNDS			
Total funds brought forward	144,031	22,377	166,408
TOTAL FUNDS CARRIED FORWARD	125,001	22,377	147,378

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

12. FIXED ASSET INVESTMENTS

	Unlisted investments £
MARKET VALUE	
At 1 January 2023 and 31 December 2023	1
	<hr/>
NET BOOK VALUE	
At 31 December 2023	1
	<hr/>
At 31 December 2022	1
	<hr/>

There were no investment assets outside the UK.

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2023	2022
	£	£
Trade debtors	32,418	17,500
Prepayments	8,335	393
	<hr/>	<hr/>
	40,753	17,893
	<hr/>	<hr/>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Deferred income

	2023	2022
	£	£
Deferred income at 1 January 2022	23,000	14,000
Resources deferred during the year	23,780	23,000
Amounts released from prior year	(23,000)	(14,000)
	<hr/>	<hr/>
Deferred income at 31 December 2022	23,780	23,000
	<hr/>	<hr/>

Deferred income relates to income received in the year specifically relating to performance conditions to be met in the following year.

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

15. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR

	2023	2022
	£	£
Bursary Fund - support for members to attend meetings	24,303	20,381
Swansea health economics work to accompany HCCUK Projec	-	(736)
BLNA restricted fund	12,479	12,479
	<u>36,782</u>	<u>32,124</u>

16. MOVEMENT IN FUNDS

	At 1.1.23	Net movement in funds	At 31.12.23
	£	£	£
Unrestricted funds			
General fund	125,001	47,878	172,879
Restricted funds			
BASL nurses fund	6,627	-	6,627
CCA UK Neil Blenkinsop donation for research only	15,750	-	15,750
	<u>22,377</u>	<u>-</u>	<u>22,377</u>
TOTAL FUNDS	<u>147,378</u>	<u>47,878</u>	<u>195,256</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	533,539	(485,661)	47,878
TOTAL FUNDS	<u>533,539</u>	<u>(485,661)</u>	<u>47,878</u>

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Notes to the Financial Statements - continued
for the year ended 31 DECEMBER 2023**

16. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.1.22 £	Net movement in funds £	At 31.12.22 £
Unrestricted funds			
General fund	144,031	(19,030)	125,001
Restricted funds			
BASL nurses fund	6,627	-	6,627
CCA UK Neil Blenkinsop donation for research only	15,750	-	15,750
	<u>22,377</u>	<u>-</u>	<u>22,377</u>
TOTAL FUNDS	<u>166,408</u>	<u>(19,030)</u>	<u>147,378</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	397,892	(416,922)	(19,030)
TOTAL FUNDS	<u>397,892</u>	<u>(416,922)</u>	<u>(19,030)</u>

17. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2023.

**THE BRITISH ASSOCIATION FOR THE STUDY OF
THE LIVER**

**Detailed Statement of Financial Activities
for the year ended 31 DECEMBER 2023**

	2023 £	2022 £
INCOME AND ENDOWMENTS		
Membership subscriptions		
Grants	12,729	-
Subscriptions	103,654	99,160
	<hr/> 116,383	<hr/> 99,160
Conference fees & sponsorship income		
Conference income	413,049	297,904
Interest receivable		
Interest receivable	4,107	828
	<hr/>	<hr/>
Total incoming resources	533,539	397,892
EXPENDITURE		
Direct conference costs		
Annual conference costs	274,284	194,548
Annual support to UKLA	13,250	11,500
	<hr/> 287,534	<hr/> 206,048
Other associated conference costs		
Travel & hotels	12,511	2,242
Artwork/design & print	4,216	3,536
CPD application	956	284
Bank charges	5,282	4,196
Website	4,408	6,185
Secretarial support costs	8,044	5,751
EBS Costs	170,635	175,204
Partial exemption input VAT	(16,939)	-
	<hr/> 189,113	<hr/> 197,398
Support costs		
Governance costs		
Accountancy fees	5,012	5,047
Other legal and professional	4,002	8,429
	<hr/> 9,014	<hr/> 13,476
Total resources expended	485,661	416,922
	<hr/>	<hr/>
Net income/(expenditure)	47,878	(19,030)
	<hr/>	<hr/>

This page does not form part of the statutory financial statements